Anagrelide Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 0.5 mg
Reference Brands: Agrylin (USA)
Category:
Blood Disorder
Anagrelide Hydrochloride is available in Capsules
and strengths such as 0.5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Anagrelide Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Anagrelide Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Anagrelide, marketed under brand names such as Agrylin, Xagrid, Shire, and Thromboreductin, is a medication used primarily for the treatment of essential thrombocytosis (essential thrombocythemia), a condition characterized by the overproduction of blood platelets. It is particularly indicated for patients whose current therapy is insufficient to control platelet levels. Anagrelide works by selectively inhibiting the maturation of megakaryocytes in the bone marrow, the cells responsible for producing platelets, thereby reducing platelet counts and lowering the risk of thrombosis and related complications.
Anagrelide is typically prescribed for patients who meet specific clinical criteria, such as age over 60 years, platelet counts exceeding 1000 billion/L, or a history of thrombosis. The drug is administered orally in capsule form, with careful dose titration and regular monitoring of blood counts to ensure safety and effectiveness. In addition to essential thrombocytosis, anagrelide has also been explored in the treatment of chronic myeloid leukemia. Controlled-release formulations, such as GALE-401, are currently under investigation in phase III clinical trials to optimize dosing and therapeutic outcomes for patients with essential thrombocytosis.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing